Novoleucel - CBio A/S
Alternative Names: CB-105Latest Information Update: 06 Aug 2024
At a glance
- Originator Cbio A/S
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cervical cancer; Head and neck cancer; Lung cancer; Malignant melanoma
- Research Colorectal cancer; Ovarian cancer; Pancreatic cancer; Renal cancer
Most Recent Events
- 06 Aug 2024 Preclinical trials in Head and neck cancer in Denmark (Parenteral) prior to August 2024 (CBio pipeline, August 2024)
- 06 Aug 2024 Preclinical trials in Lung cancer in Denmark (Parenteral) prior to August 2024 (CBio pipeline, August 2024)
- 06 Aug 2024 Preclinical trials in Malignant melanoma in Denmark (Parenteral) prior to August 2024 (CBio pipeline, August 2024)